• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.

作者信息

Lai Yong-Rong, Cappellini Maria Domenica, Aydinok Yesim, Porter John, Karakas Zeynep, Viprakasit Vip, Siritanaratkul Noppadol, Kattamis Antonis, Liu Rongrong, Izquierdo Miguel, Lasher Janet, Govindaraju Sameera, Taher Ali

机构信息

Department of Hematology, Guangxi Medical University, Nanning, China.

Department of Internal Medicine, Università di Milano, Milan, Italy.

出版信息

Am J Hematol. 2022 Aug;97(8):E281-E284. doi: 10.1002/ajh.26592. Epub 2022 May 27.

DOI:10.1002/ajh.26592
PMID:35560253
Abstract
摘要

相似文献

1
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.地拉罗司治疗非输血依赖型地中海贫血铁过载患者的开放标签、多中心、疗效及安全性研究（THETIS）：5年结果
Am J Hematol. 2022 Aug;97(8):E281-E284. doi: 10.1002/ajh.26592. Epub 2022 May 27.
2
Efficacy and Safety of a Dispersible Tablet of GPO-Deferasirox Monotherapy among Children with Transfusion-Dependent Thalassemia and Iron Overload.GPO-地拉罗司分散片单药治疗输血依赖型地中海贫血和铁过载儿童的疗效和安全性。
Hemoglobin. 2024 Jan;48(1):47-55. doi: 10.1080/03630269.2024.2311360. Epub 2024 Feb 18.
3
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.优化地拉罗司用于非输血依赖型地中海贫血患者的铁螯合治疗：THETIS研究的1年结果
Blood Cells Mol Dis. 2016 Mar;57:23-9. doi: 10.1016/j.bcmd.2015.11.002. Epub 2015 Nov 11.
4
A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.对重型β地中海贫血铁过载患者使用地拉罗司进行的15年随访。
Br J Haematol. 2020 Nov;191(3):e81-e83. doi: 10.1111/bjh.17035. Epub 2020 Sep 18.
5
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.地拉罗司显著减少非输血依赖型地中海贫血的铁过载：一项前瞻性、随机、双盲、安慰剂对照研究的 1 年结果。
Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15.
6
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007476. doi: 10.1002/14651858.CD007476.pub2.
7
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.地拉罗司降低和预防β-地中海贫血心脏铁过载的疗效。
Blood. 2010 Mar 25;115(12):2364-71. doi: 10.1182/blood-2009-04-217455. Epub 2009 Dec 8.
8
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.口服螯合剂地拉罗司与去铁酮联合治疗输血依赖型地中海贫血患儿铁过载的疗效和安全性：一项前瞻性观察研究。
Indian J Pediatr. 2021 Apr;88(4):330-335. doi: 10.1007/s12098-020-03442-5. Epub 2020 Jul 13.
9
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.地拉罗司治疗非输血依赖型地中海贫血综合征患者的概况。
Drug Des Devel Ther. 2015 Dec 16;9:6475-82. doi: 10.2147/DDDT.S40694. eCollection 2015.
10
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.去铁酮与地拉罗司联合用药对重型β地中海贫血铁过载患者有效：一项前瞻性、单中心、开放标签研究。
Pediatr Blood Cancer. 2015 Sep;62(9):1592-6. doi: 10.1002/pbc.25533. Epub 2015 Mar 28.

引用本文的文献

1
[Guidelines for iron chelation therapy in thalassemia in China (2025)].《中国地中海贫血铁螯合治疗指南（2025年版）》
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Apr 15;27(4):377-388. doi: 10.7499/j.issn.1008-8830.2411001.
2
How I treat non-transfusion-dependent β-thalassemia.我如何治疗非输血依赖型β-地中海贫血。
Blood. 2023 Sep 14;142(11):949-960. doi: 10.1182/blood.2023020683.